In any cardiac patient, efforts should be made to avoid volume overload, especially around the time of surgery. Continuous retrograde Del Nido cardioplegia, a common practice for maintaining cardiac arrest during a procedure when a patient has patent circulation, has the unintended side effect of significantly adding to the net fluid infused into the patient. Systemic hyperkalemia has been induced to reduce the amount of cardioplegia needed to maintain cardiac electromechanical arrest. To supplement knowledge regarding this technique, we report our experiences using systemic hyperkalemia in the context of the use of Del Nido cardioplegia.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8865256PMC
http://dx.doi.org/10.1080/08998280.2021.2002790DOI Listing

Publication Analysis

Top Keywords

systemic hyperkalemia
12
cardiac arrest
8
del nido
8
nido cardioplegia
8
cardiac
5
inducing systemic
4
hyperkalemia cardiac
4
arrest cardiopulmonary
4
cardiopulmonary bypass
4
bypass patent
4

Similar Publications

Pseudohypoaldosteronism (PHA) is a rare disorder that, if not promptly recognized and treated, can lead to life-threatening hyperkalemia resulting in cardiac arrest and death. Systemic PHA is caused by variants that deactivate the epithelial sodium channel (ENaC) subunits. Management is challenging due to high-dose oral replacement therapy, and patients with systemic PHA require lifelong treatment.

View Article and Find Full Text PDF

We conducted a high-risk redo mitral valve replacement through a right mini-thoracotomy without rib spreading (redo-MICS MVR) under systemic hyperkalemia combined with circulatory arrest to circumvent complications associated with cardioplegia delivery. The patient, a 75-year-old man, had a predicted mortality rate of 20%. Initial antegrade cardioplegia successfully induced cardiac arrest, which was administered every 30 min.

View Article and Find Full Text PDF

COL4A2-Related Disorder Presenting in Adulthood With Rhabdomyolysis.

Am J Med Genet A

December 2024

Department of Clinical Genomics, Mayo Clinic, Scottsdale, Arizona, USA.

The alpha 1 and 2 chains of type IV collagen, encoded by the COL4A1 (MIM 120130) and COL4A2 (MIM 120090) respectively, play essential roles in the vascular basement membranes. Pathogenic variants in COL4A1/ COL4A2 are associated with autosomal dominant cerebral angiopathies. The clinical manifestations of COL4A1/COL4A2-related disorders include: aneurysms, intracerebral hemorrhage, polymicrogyria, porencephaly, heterotopia, periventricular leukomalacia, epilepsy, and neurodevelopmental disorders.

View Article and Find Full Text PDF

Mitochondrial disorders are often underrecognized as potential causes of rhabdomyolysis, a condition characterized by acute muscle breakdown that can lead to local and potentially systemic complications, with the possibility of being life-threatening. Accounts of rhabdomyolysis as a peri-operative complication associated with mitochondrial disorders are rare; therefore, this study is noteworthy. We describe a case of rhabdomyolysis that occurred during the peri-operative period in a middle-aged male with Charcot-Marie-Tooth (CMT) disease-like peripheral neuropathy.

View Article and Find Full Text PDF
Article Synopsis
  • Recessive dystrophic epidermolysis bullosa (RDEB) is a severe skin condition that causes blisters and other complications, and this study tested the safety of losartan, a medication that may slow its progression.
  • The study was a phase 1/2 trial involving children aged 2-16 with confirmed RDEB, focusing on identifying any serious side effects of losartan over a treatment period of 10 months.
  • Primary safety concerns monitored included severe drops in blood pressure, allergic reactions, and changes in potassium levels, along with evaluating the drug's effectiveness through various clinical scores.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!